# Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

> **NCT00780325** · PHASE1 · TERMINATED · sponsor: **University of Pennsylvania** · enrollment: 26 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** CG100649 (2 mg)
- **DRUG:** Celecoxib
- **DRUG:** Placebo capsules
- **DRUG:** Naproxen
- **DRUG:** Acetazolamide
- **DRUG:** CG100649 (8 mg)

## Key facts

- **NCT ID:** NCT00780325
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** A total of three parts were planned for this study. The sponsor funded only Part 1, so that neither Part 2 nor Part 3 of this study has been conducted.
- **Last updated:** 2014-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00780325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00780325, "Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00780325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*